Neurocrine Biosciences
NBIX
$142.00
Share price
2.54%
Change (1 day)
44.68%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - P/B ratio
P/B ratio as of May 2024 : 5.84
According to Neurocrine Biosciences
's latest financial reports the company has a price-to-book ratio of 5.84.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Neurocrine Biosciences - P/B ratio (from 2001 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 5.80 | -13.73% |
| 2022-12-31 | 6.72 | 14.33% |
| 2021-12-31 | 5.88 | -26.05% |
| 2020-12-31 | 7.95 | -48.94% |
| 2019-12-31 | 15.6 | 15.47% |
| 2018-12-31 | 13.5 | -26.91% |
| 2017-12-31 | 18.5 | 72.81% |
| 2016-12-31 | 10.7 | -7.13% |
| 2015-12-31 | 11.5 | 40.46% |
| 2014-12-31 | 8.19 | 56.68% |
| 2013-12-31 | 5.22 | 62.26% |
| 2012-12-31 | 3.22 | -58.81% |
| 2011-12-31 | 7.82 | -63.93% |
| 2010-12-31 | 21.7 | -28.38% |
| 2009-12-31 | 30.3 | 801% |
| 2008-12-31 | 3.36 | 129.43% |
| 2007-12-31 | 1.46 | 16.64% |
| 2006-12-31 | 1.26 | -78.98% |
| 2005-12-31 | 5.97 | 30.56% |
| 2004-12-31 | 4.57 | -7.13% |
| 2003-12-31 | 4.92 | -21.13% |
| 2002-12-31 | 6.24 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.80 | -69.16% | 🇺🇸 USA |
 AbbVie ABBV | 27.4 | 369.90% | 🇺🇸 USA |
 Eli Lilly LLY | 56.3 | 863.90% | 🇺🇸 USA |
 Repligen
RGEN | 4.89 | -16.26% | 🇺🇸 USA |
 Athersys ATHX | -0.0229 | -100.39% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | 3.02 | -48.21% | 🇺🇸 USA |
 Palatin Technologies PTN | -3.42 | -158.49% | 🇺🇸 USA |
 Royalty Pharma RPRX | 1.66 | -71.53% | 🇬🇧 UK |